{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Steroid+eye+drops&page=2",
    "query": {
      "intervention": "Steroid eye drops",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Steroid+eye+drops&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T13:56:45.165Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00870103",
      "title": "Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2008-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2010-03-09",
      "last_synced_at": "2026-09-27T13:56:45.165Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00870103"
    },
    {
      "nct_id": "NCT01456780",
      "title": "Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Meibomian Gland Dysfunction",
        "Posterior Blepharitis"
      ],
      "interventions": [
        {
          "name": "Loteprednol/tobramycin",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol",
          "type": "DRUG"
        },
        {
          "name": "B+L Advanced Eye Relief Lubricant Drop",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2011-08",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2017-08-01",
      "last_synced_at": "2026-09-27T13:56:45.165Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01456780"
    },
    {
      "nct_id": "NCT01858922",
      "title": "Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Disease"
      ],
      "interventions": [
        {
          "name": "ABVE-PC",
          "type": "DRUG"
        },
        {
          "name": "DECA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "2012-12-19",
      "completion_date": "2019-08-12",
      "has_results": false,
      "last_update_posted_date": "2024-01-12",
      "last_synced_at": "2026-09-27T13:56:45.165Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01858922"
    },
    {
      "nct_id": "NCT00689078",
      "title": "Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Prednisolone Acetate 1%",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Acetate 0.12%",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol Etabonate 0.2%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ORA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2008-05",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2020-09-02",
      "last_synced_at": "2026-09-27T13:56:45.165Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00689078"
    },
    {
      "nct_id": "NCT05542381",
      "title": "The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Loteprednol Etabonate Ophthalmic Gel [Lotemax]",
          "type": "DRUG"
        },
        {
          "name": "Refresh Lubricant Eye Drops [Artificial Tears]",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Virginia Polytechnic Institute and State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2022-12-22",
      "completion_date": "2025-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-09-27T13:56:45.165Z",
      "location_count": 1,
      "location_summary": "Roanoke, Virginia",
      "locations": [
        {
          "city": "Roanoke",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05542381"
    },
    {
      "nct_id": "NCT04246801",
      "title": "Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Clobetasol propionate",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Salvat",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2020-06-10",
      "completion_date": "2021-05-19",
      "has_results": true,
      "last_update_posted_date": "2022-12-22",
      "last_synced_at": "2026-09-27T13:56:45.165Z",
      "location_count": 22,
      "location_summary": "Chandler, Arizona • Beverly Hills, California • Glendora, California + 19 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendora",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04246801"
    },
    {
      "nct_id": "NCT02030990",
      "title": "The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Corneal Opacity"
      ],
      "interventions": [
        {
          "name": "Mitomycin-C",
          "type": "DRUG"
        },
        {
          "name": "Fluorometholone 1% topical ocular steroid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United States Naval Medical Center, San Diego",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 300,
      "start_date": "2014-08",
      "completion_date": "2023-07",
      "has_results": false,
      "last_update_posted_date": "2022-04-15",
      "last_synced_at": "2026-09-27T13:56:45.165Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02030990"
    },
    {
      "nct_id": "NCT06681688",
      "title": "Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}",
          "type": "DRUG"
        },
        {
          "name": "Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inder Paul Singh, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2024-07-10",
      "completion_date": "2025-08",
      "has_results": false,
      "last_update_posted_date": "2024-11-29",
      "last_synced_at": "2026-09-27T13:56:45.165Z",
      "location_count": 2,
      "location_summary": "Venice, Florida • Racine, Wisconsin",
      "locations": [
        {
          "city": "Venice",
          "state": "Florida"
        },
        {
          "city": "Racine",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06681688"
    },
    {
      "nct_id": "NCT01102244",
      "title": "A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Blepharitis"
      ],
      "interventions": [
        {
          "name": "Tobradex ST",
          "type": "DRUG"
        },
        {
          "name": "Azasite",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2010-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-06-11",
      "last_synced_at": "2026-09-27T13:56:45.165Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01102244"
    },
    {
      "nct_id": "NCT04005079",
      "title": "Pilocarpine After Combined Cataract/Trabectome Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Pilocarpine",
          "type": "DRUG"
        },
        {
          "name": "Ofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "30 Years to 100 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-06-05",
      "completion_date": "2021-01-21",
      "has_results": false,
      "last_update_posted_date": "2022-04-07",
      "last_synced_at": "2026-09-27T13:56:45.165Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04005079"
    }
  ]
}